Source: Annual Congress 2004 - Clinical studies on acute respiratory failure in COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
P. Sattonnet, P. Plaisance, L. Lecourt, E. Vicaut, F. Adnet, C. Chollet (Thionville, Paris, France). The efficacy of hélium-oxygen mixture (65%-35%) in acute asthma exacerbations. Eur Respir J 2004; 24: Suppl. 48, 3354

Member's Comments

No comment yet.

Related content which might interest you: Efficacy of administration of 0.02% solution of decamethoxine via nebulizer in patients with infectious exacerbations of COPD Source: Annual Congress 2013 –COPD treatment Year: 2013 Surfactant protein D (SPD) like marker of effectiveness in patients (pts) with acute exacerbations (AE) of COPD ofphosphatidylcholine treatment outcomes Source: International Congress 2015 – Different data in COPD Year: 2015 Ceruloplasmine efficacy in patients with asthma exacerbations Source: Annual Congress 2011 - Novel mechanisms in lung injury Year: 2011 Vascular-platelet hemostasis parameters in the stable phase and in acute exacerbation (AE) of COPD Source: International Congress 2015 – COPD: exacerbations, gas exchange and associated dysfunction Year: 2015 Omalizumab reduces asthma exacerbations in children (6–<12 years) with moderate-to-severe allergic (IgE-mediated) asthma irrespective of baseline LABA use Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues Year: 2009 Clinical effectiveness of nebulized budesonide in the treatment of acute asthma and exacerbations of chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2001; 18: Suppl. 33, 146s Year: 2001 Is the asthma control questionnaire (ACQ) usefull during acute moderate to severe (AMS) asthma exacerbations (AE)? Source: Eur Respir J 2004; 24: Suppl. 48, 591s Year: 2004 Efficacy of levofloxacin (LVF) in the treatment of acute exacerbations of chronic bronchitis (AECB) in patients with risk factors Source: Annual Congress 2003 - Acute exacerbations of asthma and COPD Year: 2003 Acute effects of higher than customary doses of salmeterol (SM) and salbutamol (SB) in patients with acute exacerbation of COPD Source: Eur Respir J 2001; 18: Suppl. 33, 514s Year: 2001 Formoterol (Modulite), tiotropium and their combination in patients with acute exacerbation of chronic bronchitis: preliminary data Source: Eur Respir J 2005; 26: Suppl. 49, 285s Year: 2005 Comparison of the acute effects of formoterol (F) and formoterol/budesonide combination (FBC) on blood-gas tensions in patients with acute exacerbation of COPD (AECOPD) Source: Annual Congress 2003 - Progress on therapy for chronic obstructive pulmonary disease Year: 2003 Characterisation of exacerbations of severe eosinophilic asthma (SEA) on mepolizumab compared to placebo Source: International Congress 2017 – Asthma management Year: 2017 Indacaterol/glycopyrronium (IND/GLY) reduces exacerbation and improves lung function versus salmeterol/fluticasone (SFC) in patients with and without prior ICS use: The FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 Co-morbidity and hospitalization rate in patients (pts) with acute exacerbation (AE) of COPD Source: International Congress 2015 – Different data in COPD Year: 2015 Indacaterol/glycopyrronium (IND/GLY) reduces exacerbations compared with salmeterol/fluticasone (SFC) in various sub-groups from the FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 Erdosteine improves airflow in patients with severe exacerbation of COPD (AECOPD) Source: International Congress 2016 – Novel avenues in the treatment of COPD II Year: 2016 Efficacy of inhaled heparin is effective in the treatment of acute exacerbation of asthma Source: Annual Congress 2007 - New drugs for asthma Year: 2007 Once-daily indacaterol/glycopyrronium (IND/GLY) reduces all exacerbations compared with twice-daily salmeterol/fluticasone (SFC) in COPD patients with ≥1 exacerbation in the previous year: The FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 Effect of fluticasone furoate (FF)/vilanterol (VI) compared with VI on acute exacerbations of COPD (AECOPD): A post-hoc analysis by baseline airflow obstruction Source: International Congress 2015 – New data on established treatments for COPD Year: 2015 Efficacy and safety of adding erdosteine in acute exacerbations of COPD (AECOPD): a comparative analysis with the standard treatment Source: Virtual Congress 2020 – Clinical studies of COPD: combination inhalers and much more Year: 2020